Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1
Anti-PD1/PDL1 monotherapy has failed to acquire sufficiently ideal results in most solid tumors. Mesenchymal stem cells (MSCs) have been reported to exert therapeutic effects on some tumors, but the functions of MSCs in colorectal cancer (CRC) need further research. In this study, we aimed to invest...
Main Authors: | Jize Liu, Xiaomin Ma, Chuxuan Liu, Yang Cheng, Bingjun Li, Wenjie Zhang, Runzhi Zeng, Qishuai Chen, Yun Zhang, Sanyuan Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1136614/full |
Similar Items
-
RELATIONSHIP BETWEEN T CELL IMMUNITY PARAMETERS AND SMOOTH-CELL CARCINOMA ANTIGEN (SCCA) CONTENTS IN BLOOD SERUM FROM THE PATIENTS WITH LOCAL DISSEMINATED FORMS OF UTERINE CERVIX CANCER
by: I. L. Baturina, et al.
Published: (2014-07-01) -
Emerging T cell immunoregulatory mechanisms in multiple sclerosis and Alzheimer’s disease
by: Daniel Hawiger
Published: (2024-02-01) -
CAR‐T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment
by: Audrey Abecassis, et al.
Published: (2022-08-01) -
The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy
by: Apoorvi Chaudhri, et al.
Published: (2023-09-01) -
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)